Page 97 - TD-3-1

Tumor Discovery MMP-1 as a potential biomarker for gastric cancer

carcinoma. Cancer Lett. 2016;377(1):97-104. doi: 10.3892/mmr.2018.8722
doi: 10.1016/j.canlet.2016.04.034 40. Chrom P, Stec R, Szczylik C. Second-line treatment of
advanced gastric cancer: Current options and future
29. Peng HH, Zhang X, Cao PG. MMP-1/PAR-1 signal transduction perspectives. Anticancer Res. 2015;35(9):4575-4583.
axis and its prognostic impact in esophageal squamous cell
carcinoma. Braz J Med Bioll Res. 2012;45(1):86-92. 41. Wang X, Deng J, Liang H. Well differentiated carcinoma
with a poor prognosis: A retrospective analysis of papillary
doi: 10.1590/s0100-879x2011007500152
gastric adenocarcinoma. Surg Today. 2021;51(8):1387-1396.
30. Zhou J, Xu M, Tan J, Zhou L, Dong F, Huang T. MMP1 doi: 10.1007/s00595-021-02289-3
acts as a potential regulator of tumor progression and
dedifferentiation in papillary thyroid cancer. Front Oncol. 42. Digklia A, Wagner AD. Advanced gastric cancer: Current
2022;12:1030590. treatment landscape and future perspectives. World J
Gastroenterol. 2016;22(8):2403-2414.
doi: 10.3389/fonc.2022.1030590
doi: 10.3748/wjg.v22.i8.2403
31. Shen Q, Polom K, Williams C, et al. A targeted proteomics
approach reveals a serum protein signature as diagnostic 43. Wei R, Du X, Wang J, et al. Risk and prognosis of subsequent
biomarker for resectable gastric cancer. EBioMedicine. primary gastric cancer. Oncol Res Treat. 2022;45(4):186-196.
2019;44:322-333. doi: 10.1159/000521846
doi: 10.1016/j.ebiom.2019.05.044 44. Chang JY, Shim KN, Tae CH, et al. Comparison of clinical
32. Wang K, Zheng J, Yu J, et al. Knockdown of MMP1 inhibits outcomes after endoscopic submucosal dissection and
the progression of colorectal cancer by suppressing the surgery in the treatment of early gastric cancer: A single-
PI3K/Akt/cmyc signaling pathway and EMT. Oncol institute study. Medicine (Baltimore). 2017;96(30):e7210.
Rep. 2020;43(4):1103-1112. doi: 10.1097/md.0000000000007210
doi: 10.3892/or.2020.7490 45. Kumar S, Katona BW, Long JM, et al. Endoscopic
33. Kumar P, Sebastian A, Verma K, et al. mRNA expression ultrasound has limited utility in diagnosis of gastric cancer
analysis of E-cadherin, VEGF, and MMPs in gastric cancer: in carriers of CDH1 mutations. Clin Gastroenterol Hepatol.
A pilot study. Indian J Surg Oncol. 2021;12(Suppl 1):85-92. 2020;18(2):505-508.e1.
doi: 10.1007/s13193-020-01096-5 doi: 10.1016/j.cgh.2019.04.064
34. Matsuoka T, Yashiro M. Biomarkers of gastric cancer: 46. Wang F, Hu D, Lou X, et al. BNIP3 and DAPK1 methylation
Current topics and future perspective. World J Gastroenterol. in peripheral blood leucocytes are noninvasive biomarkers
2018;24(26):2818-2832. for gastric cancer. Gene. 2024;898:148109.
doi: 10.3748/wjg.v24.i26.2818 doi: 10.1016/j.gene.2023.148109
35. Sun Y, Jin J, Jing H, et al. ITIH4 is a novel serum biomarker 47. Hu D, Lou X, Meng N, et al. Peripheral blood-based
for early gastric cancer diagnosis. Clin Chim Acta. DNA methylation of long non-coding RNA H19
2021;523:365-373. and metastasis-associated lung adenocarcinoma
transcript 1 promoters are potential non-invasive
doi: 10.1016/j.cca.2021.10.022 biomarkers for gastric cancer detection. Cancer Control.
36. Wu D, Zhang P, Ma J, et al. Serum biomarker panels for the 2021;28:10732748211043667.
diagnosis of gastric cancer. Cancer Med. 2019;8(4):1576-1583. doi: 10.1177/10732748211043667
doi: 10.1002/cam4.2055 48. Fan H, Li X, Li ZW, et al. Urine proteomic signatures
37. Guo X, Peng Y, Song Q, et al. A liquid biopsy signature predicting the progression from premalignancy to malignant
for the early detection of gastric cancer in patients. gastric cancer. EBioMedicine. 2022;86:104340.
Gastroenterology. 2023;165(2):402-413.e13. doi: 10.1016/j.ebiom.2022.104340
doi: 10.1053/j.gastro.2023.02.044 49. Kao HW, Pan CY, Lai CH, et al. Urine miR-21-5p as
38. Zheng L, Wu C, Xi P, et al. The survival and the long-term a potential non-invasive biomarker for gastric cancer.
trends of patients with gastric cancer in Shanghai, China. Oncotarget. 2017;8(34):56389-56397.
BMC Cancer. 2014;14:300. doi: 10.18632/oncotarget.16916
doi: 10.1186/1471-2407-14-300 50. Hoshino I. The usefulness of microRNA in urine and saliva
as a biomarker of gastroenterological cancer. Int J Clin
39. Yang J, Bo L, Han T, Ding D, Nie M, Yin K. Pathway-and clinical-
factor-based risk model predicts the prognosis of patients with Oncol. 2021;26(8):1431-1440.
gastric cancer. Mol Med Rep. 2018;17(5):6345-6356. doi: 10.1007/s10147-021-01911-1

Volume 3 Issue 1 (2024) 9 https://doi.org/10.36922/td.1973